Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04707248 · ClinicalTrials.gov registry record · Phase 1

A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

A Phase 1 study of Renal Cell Carcinoma and Ovarian Tumor, sponsored by Daiichi Sankyo.

Active
Registry status
Phase 1
Development phase
179
Enrollment target
13
Study locations

NCT04707248 is a Phase 1 study of Renal Cell Carcinoma and Ovarian Tumor that is active but no longer recruiting, run by Daiichi Sankyo. The registered enrollment target is 179 participants, below the 241-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (26% lower). The trial reports 13 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04707248, a Phase 1 study of Renal Cell Carcinoma and Ovarian Tumor, is active but no longer recruiting, sponsored by Daiichi Sankyo.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
179 participants
Enrollment target
13
Study locations

Study Summary

This clinical trial will evaluate raludotatug deruxtecan (R-DXd; DS-6000a) in participants with advanced renal cell carcinoma (RCC) and ovarian cancer (OVC). The main goals of this study will be to investigate the recommended dose of R-DXd that can be given safely to participants, assess the adverse events of R-DXd, and evaluate the effectiveness of R-DXd.

Conditions Studied

Renal Cell Carcinoma Ovarian Tumor

Interventions

  • DRUG DS-6000a

Study Locations (13)

Other

  • National Hospital Organization Kyusyu Cancer Center - Fukuoka
  • The Cancer Institute Hospital of Japanese Foundation for Cancer Research - Kōtoku
  • National Hospital Organization Shikoku Cancer Center - Matsuyama
  • Shizuoka Cancer Center - Nakatogari
  • Saitama Medical University International Medical Center - Saitama

Tennessee

  • SCRI Oncology Partners - Nashville
  • Vanderbilt-Ingram Cancer Center - Nashville

Tokyo

  • National Cancer Center Hospital - Chuo Ku
  • National Cancer Center Hospital East - Kashiwa-shi

Arizona

  • Arizona Oncology Associates, PC HOPE (A)A HOPE) - Tucson

Colorado

  • Rocky Mountain Cancer Center - Denver

Florida

  • Florida Cancer Lake Mary - Lake Mary

Oklahoma

  • Oklahoma University - Oklahoma City

Trial Details

FieldValue
Enrollment Target 179 participants
Start Date 2020-12-22
Est. Completion 2026-06-30
Phase Phase 1

Sponsor

Daiichi Sankyo

236 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04707248

The ClinicalTrials.gov registry entry for NCT04707248 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 179 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 241-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (26% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which DS-6000a is the first listed.

NCT04707248 reports 13 study locations spanning 7 distinct geographic areas - top geographies include Other, Tennessee, Tokyo.

Frequently Asked Questions

What is clinical trial NCT04707248 about?

NCT04707248 is a clinical study titled "A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors". This clinical trial will evaluate raludotatug deruxtecan (R-DXd; DS-6000a) in participants with advanced renal cell carcinoma (RCC) and ovarian cancer (OVC). The main goals of this study will be to investigate the recommended dose of R-DXd that can be given safely to participants, assess the adverse...

What is the current status of trial NCT04707248?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 179 participants. The study started on 2020-12-22. Estimated completion is 2026-06-30.

What conditions does trial NCT04707248 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma, Ovarian Tumor.

What interventions are being tested in trial NCT04707248?

The interventions under investigation include: DS-6000a (DRUG).

Who is sponsoring clinical trial NCT04707248?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04707248 being conducted?

This trial has 13 study locations across Arizona, Colorado, Florida, Oklahoma, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Renal Cell Carcinoma

All registered trials for this condition

Ovarian Tumor

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.